You are here

J&J to pay US$2.2b in fines for improper marketing of drug

Firm acknowledges it promoted anti-psychotic drug for unapproved uses

[NEW YORK] Johnson & Johnson has agreed to pay more than US$2.2 billion in criminal and civil fines to settle accusations that it improperly promoted the anti-psychotic drug Risperdal to older adults, children and people with developmental disabilities, the Justice Department said.


Market voices on: